9 recruiting, 3 not yet recruiting, 1 approved for marketing. 6 Phase 1, 5 Phase 2, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Recruiting 4, Not yet recruiting 2 |
| Phase 2 | 5 | Recruiting 3, Not yet recruiting 2 |
| Phase 3 | 4 | Recruiting 4 |
Follow Daraxonrasib: new trials by email Literature Review of Daraxonrasib trials Research Report on Daraxonrasib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Daraxonrasib in Resectable PDAC Daraxonrasib, Surgical Resection, Adjuvant Chemotherapy - Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer | Phase 1 | Not yet recruiting | Dana-Farber Cancer Institute | 30 | 2027-04-13 | 2026-10-27 |
| Testing the Addition of an Anti-Cancer Drug, Daraxonrasib, for Relapsed or Refractory Solid Tumors With RAS Mutations Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Childhood Malignant Solid Neoplasm, Recurrent Childhood Neuroblastoma | Phase 1 / Phase 2 | Not yet recruiting | Children's Oncology Group | 77 | 2027-04-09 | 2026-09-15 |
| Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer Daraxonrasib - Biliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc) | Phase 2 | Not yet recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 55 | 2026-11-01 | 2026-08-28 |
| First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer SNV1521, daraxonrasib - Pancreatic Cancer, Pancreatic Acinar Carcinoma | Phase 1 | Recruiting | ParVation Therapeutics, Inc. | 40 | 2026-09-01 | 2026-10-27 |
| Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma daraxonrasib, gemcitabine, nab-paclitaxel - Pancreatic Cancer, Pancreatic Cancer Metastatic | Phase 3 | Recruiting | Revolution Medicines, Inc. | 400 | 2026-08-28 | 2026-10-16 |
| A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) BMS-986504, Daraxonrasib, Nivolumab + Relatlimab FDC - Solid Tumors | Phase 2 | Recruiting | Bristol-Myers Squibb | 260 | 2026-07-27 | 2026-10-06 |
| Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma daraxonrasib, gemcitabine, nab-paclitaxel - Pancreatic Cancer, Pancreatic Cancer Metastatic | Phase 3 | Recruiting | Revolution Medicines, Inc. | 900 | 2026-03-09 | 2026-10-02 |
| Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors Daraxonrasib, Elironrasib, Zoldonrasib - Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Revolution Medicines, Inc. | 370 | 2026-01-30 | 2026-08-03 |
| Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors RMC-5127, daraxonrasib, cetuximab - Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) | Phase 1 | Recruiting | Revolution Medicines, Inc. | 574 | 2026-01-08 | 2026-09-17 |
| Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) daraxonrasib - Pancreatic Cancer, PDAC | Phase 3 | Recruiting | Revolution Medicines, Inc. | 500 | 2025-12-15 | 2026-10-23 |
| Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) daraxonrasib, docetaxel - NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer | Phase 3 | Recruiting | Revolution Medicines, Inc. | 590 | 2025-05-06 | 2026-09-29 |
| Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors Elironrasib, Daraxonrasib - Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer | Phase 1 / Phase 2 | Recruiting | Revolution Medicines, Inc. | 534 | 2023-11-14 | 2026-09-22 |
| Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma daraxonrasib - PDAC, PDAC - Pancreatic Ductal Adenocarcinoma | Approved for marketing | Revolution Medicines, Inc. | 2026-09-01 |
Pancreatic Neoplasms (9) · Carcinoma, Non-Small-Cell Lung (4) · Colorectal Neoplasms (3) · Lung Neoplasms (3) · Gastrointestinal Neoplasms (2) · Neoplasm Metastasis (2) · Appendiceal Neoplasms (1) · Biliary Tract Neoplasms (1) · Brain Neoplasms (1) · Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Pancreatic Ductal (1) · Cholangiocarcinoma (1) · Cirrhosis, Familial, with Pulmonary Hypertension (1) · Colonic Neoplasms (1)
Revolution Medicines, Inc. (8) · Bristol-Myers Squibb (1) · Children's Oncology Group (1) · Dana-Farber Cancer Institute (1) · ParVation Therapeutics, Inc. (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
United States (12) · Germany (5) · Italy (5) · Spain (5) · France (4) · Japan (4) · Puerto Rico (4) · South Korea (4) · Belgium (3) · Canada (3) · Hong Kong (3) · Netherlands (3) · United Kingdom (3) · Australia (2) · Ireland (2)
Amit J Sabnis (1) · Brandon Huffman, MD (1) · Nilo Azad, MD (1) · Revolution Medicines, Inc. (1)
2025 (1), UM1CA228823 (1)